The FDA clearance follows earlier US marketing approval for the firm's C. Difficile assay.
The investment bank adjusted its December 2020 price target for Luminex's stock to $21 and for Accelerate Diagnostics' stock to $16.
The firm's flow cytometry business contributed about $13.2 million, or 16 percent of the firm's consolidated revenue in the second quarter.
The firm said its assay is a real-time qPCR test for the direct detection of methicillin-resistant Staphylococcus aureus DNA in nasal swabs.
The firm has three clinical trials in progress to validate the clinical utility of products it soon intends to submit for regulatory clearances to the FDA.
The firm said that it placed about 50 sample-to-answer molecular systems under contract during Q1, and it had about 625 active sample-to-answer product customers.
Luminex has since fixed the problem with a software update but a similar issue with non-specific amplification has also affected two targets on BioFire's GI panel.
Natera and Veracyte both received positive news regarding local coverage determinations from Medicare contractors, while the catalysts for Fluidigm's rise were unclear.
The index — which outperformed the Dow Jones, the Nasdaq, and the Biotechnology Index this month — gained more than 8 percent.
Excluding a loss of business to LabCorp, total revenue increased 22 percent year over year in the fourth quarter, Luminex said.
A South African university has told the Wellcome Sanger Institute to return DNA samples it has from indigenous African communities, The Times reports.
The University of California, Berkeley's Rasmus Nielsen and Xinzhu Wei have retracted their CCR5 gene paper due to a technical artifact.
University of Virginia researchers are exploring a genetic risk test to gauge type 1 diabetes risk, NPR reports.
In PNAS this week: researchers compare two high-grade neuroendocrine lung cancers, height among ancient Europeans, and more.